Binimetinib 15 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 15 mg

Reference Brands: Mektovi (USA/EU)

Category: Oncology Cancer Care

Binimetinib is a MEK inhibitor used in targeted cancer therapy. It works by blocking MEK1/MEK2 enzymes in the MAPK pathway, helping slow down the growth of cancer cells. It is commonly used along with encorafenib for cancers with BRAF mutation.

Product Description:

Binimetinib inhibits MEK1 and MEK2, the kinases immediately downstream of BRAF in the MAP kinase growth pathway. It is given with encorafenib, a BRAF inhibitor, and the logic of the pairing is resistance: BRAF inhibition alone reactivates the pathway through MEK within months, and blocking both points delays that escape while also reducing the paradoxical skin toxicity that BRAF inhibitors cause on their own.

It is used with encorafenib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, and the combination is also used in BRAF-mutant colorectal cancer. Around half of melanomas carry a BRAF V600 mutation, identified by molecular testing, and the combination produces rapid responses in a disease that progresses quickly. Serous retinopathy and retinal vein occlusion require ophthalmic assessment, and left ventricular dysfunction, raised creatine kinase, rhabdomyolysis and venous thromboembolism are monitored for.

Sourcing notes. Originator product, on patent, no generic. It is prescribed only with its BRAF partner, so the two must be supplied together — an enquiry for one without the other usually indicates a misunderstanding. BRAF V600 testing is a prerequisite.